LifeMD to launch direct-to-patient program for XYOSTED in July 2026
LifeMD, Inc. is set to launch a direct-to-patient self-pay program for XYOSTED injection in July 2026 across 37 states. The program is part of a strategic co-marketing collaboration for the FDA-approved once-weekly subcutaneous testosterone auto-injector.
*this image is generated using AI for illustrative purposes only.
LifeMD, Inc. (Nasdaq: LFMD) has announced a strategic co-marketing collaboration to launch a direct-to-patient self-pay program for XYOSTED® (testosterone enanthate) injection. The program is scheduled to commence in July 2026 and will initially be accessible to patients in 37 states. XYOSTED is the only FDA-approved once-weekly subcutaneous testosterone auto-injector currently available on the market.
Program Details
The initiative focuses on providing a direct-to-patient self-pay option, aiming to improve access to the therapy. The collaboration leverages LifeMD's position as a provider of virtual primary care and specialty care to facilitate the distribution and support of the product.
Availability
| Feature | Details |
|---|---|
| Launch Date | July 2026 |
| Initial Availability | 37 states |
| Product | XYOSTED (testosterone enanthate) injection |
| Administration | Once-weekly subcutaneous auto-injector |
What are the projected revenue contributions from this collaboration to LifeMD's financials post-launch?
How will the partnership address regulatory hurdles to expand availability beyond the initial 37 states?
What impact will this direct-to-patient model have on XYOSTED's market share compared to traditional insurance-covered distribution?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
